PPAR-delta Agonist and PBC Diagnosis

CME

Investigational PPAR-delta Agonist for PBC Treatment and Race-based Considerations for PBC Diagnosis: Conference Coverage of AASLD

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: December 06, 2023

Expiration: December 05, 2024

Stuart C Gordon
Stuart C Gordon, MD, FACP, FACG, AGAF, FAASLD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Your colleague asks you about evidence for seladelpar as second-line therapy for PBC in a patient who has not achieved ALP normalization and has bothersome pruritus despite 2 years of treatment with UDCA.

Based on a recent phase III study of adding seladelpar to UDCA in people with PBC, how do you respond to your colleague’s question? Seladelpar vs placebo had improved biochemical responses and had:

2.

I am familiar with PBC data from the AASLD 2023 conference, and I plan to translate these data into current or future management strategies